Antibody

11개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved11 programs
AntibodyLimited DatastaleAstraZenecaPhase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 94Status Active
AntibodyLimited DatastaleShanghai Shengdi Pharmaceutical…Phase 2

Adebrelimab (Adebrelimab)

Pancreatic Cancer · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#Popular#monoclonal-antibody+2
Trials 92Status Recruiting
AntibodyLimited DatastaleSichuan Kelun-Biotech Biopharma…Phase 1

Drug: Tagitanlimab Drug: Capecitabine (Drug: Tagitanlimab Drug: Capecitabine)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#monoclonal-antibody#Sichuan
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 1

durvalumab (Imfinzi, IPH5401 and Durvalumab)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#monoclonal-antibody#AstraZeneca
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#AdvancedSolidTumors+2
Trials 1Status Recruiting
AntibodyLimited DatastaleEli LillyPhase 2

fulzerasib; cetuximab N01 (fulzerasib; cetuximab N01)

Colorectal Cancer; KRAS G12C Mutant Advanced Solid Tumors · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#monoclonal-antibody#KRASG12CMutantAdvancedSolidTumor+1
Trials 1Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 2

treme (tremelimumab, tremelimumab (treme))

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck · Advanced Solid Tumors & Metastatic Squam

#AdvancedSolidTumorsMetastaticSqu#Antibody#Phase2#monoclonal-antibody#AstraZeneca
Trials 1Status Active